Dulaglutide

A once-weekly GLP-1 receptor agonist approved for type 2 diabetes.

What research shows

Dulaglutide is a licensed weekly medicine with randomized evidence for glycaemic control and, through pooled class analyses, reduced cardiovascular events. It is included here for contrast: this is the evidence standard that most compounds sold as research peptides never reach.

Evidence strength

Highest evidence grade among the graded claims: A. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.